Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery
Recruiting now · Phase 4
Conditions studied: Postoperative Pain
In brief
The goal of this clinical trial\] is to further explore the effectiveness and safety of oxelidine in the treatment of moderate to severe acute pain after orthopedic surgery. The main question it aims to answer is: Pain management after orthopaedic surgery provides more effective and safe drug options, provides new options for clinical treatment, and provides a scientific basis for clinical practice. Participants will be asked to pain score in the different time, treatments they'll be given and use optimal drug. Researchers will compare analgesic effect of oxelidine of different dose.
Key facts
- Study ID
- NCT06320041
- Run by
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- People needed
- 162
- Starts
- 2024-08-01
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-02-17
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- elective orthopedic surgery under general anesthesia.
- The patient can communicate normally and has the correct expression of pain
You may not qualify if…
- Patients with advanced tumor
- Other acute and chronic pain conditions are present
- Severely obese (30 kg/m2)
- Pregnant or lactating women
- Allergy to opioids
- Sleep apnea syndrome
- Long-term opioid treatment
- Patients with mental and nervous system diseases, gastrointestinal obstruction, chronic obstructive pulmonary disease or pulmonary heart disease, cardiovascular disease
- Abnormal liver function during screening
- Abnormal renal function during screening
Where it is running
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine — Yiwu, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.